Navigation Links
Kenrico Announces Records of Patents for 2012 and Financial Targets for 2013
Date:1/22/2013

atent 4485940 – European Patent 03720506.09), was approved by Health Canada in Canada and in Europe by European Medical Device Agency. Separately, the company entered into strategic agreements with pharmaceutical companies to market nattokinase based Lexirin globally to physician for prevention of cell death. Apoptotic cell death plays a significant role in the tissue damage that occurs in association with aging and various abnormal conditions, for example, ischemia and various gastrointestinal disorders.

  •     LEXIRIN ® (US Patent 6,793,945 – 6,413,556), is a medical breakthrough in the treatment of gastrointestinal disorders, deleterious dermatological conditions, immunosuppression or immunodeficiency, reperfusion damage resulting from ischemia, cardiovascular disorders, transplantation, wound healing, tissue rejection and Alzheimer's disease, and the treatment of adverse reactions from medications. LEXIRIN also can significantly decrease conditions and diseases related to aging and blocked blood circulation. LEXIRIN has passed US FDA's Phase I human clinical trials at Alta Bates Medical Center in Berkeley.
  •     ION SHOWER HEAD EX ®, ION WATER PURIFIER ®, FOREVER ALKALINE WATER STICK PURIFIER ®. A technological advancement in water treatment technology that blends natural quartz, citrine crystals and natural minerals from Japanese hot springs for health and stress treatment.
  • Financial targets
    Kenrico continues to expect full year 2013 revenue to double from a base of $149 million in 2012.

    In addition, the company updated its anticipated consolidated tax rate to range of 10 percent.

    About Kenrico
    Kenrico is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1985, Kenrico currently discovers, develops, manufactures and markets prescription and alternative medicines to add
    '/>"/>

    Source: PRWeb
    Copyright©2012 Vocus, Inc.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    6. WuXi PharmaTech Announces Third-Quarter 2011 Results
    7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    8. Spherix Announces Third Quarter Financial Results
    9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
    11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/18/2014)... (PRWEB) November 18, 2014 Alanda ... and Transparency Reporting solutions, announced today that a ... using its Consummate Provider™ solution in both the ... a Global, SaaS based, Data Quality remediation portal, ... their third party Providers improve their ability to ...
    (Date:11/18/2014)... , Nov. 18, 2014 PDL BioPharma, Inc. ... in connection with the acquisition of Durata Therapeutics, Inc. ... connection with the termination of PDL,s credit agreement with ... outstanding of $40 million, accrued interest, and prepayment and ... into a structured financing transaction with Durata in which ...
    (Date:11/17/2014)... 17, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today the formation of a Medical Advisory Board ... Company as it advances the Phase 3 clinical ... of cutaneous T-cell lymphoma (CTCL), a rare class ...
    (Date:11/15/2014)... 2014 The redesigned ActiGraph Link ... and sleep measurement platform with a rich feature ... with multiple new channels of sensor data captured ... with Bluetooth Smart technology, the ActiGraph Link supports ... uploads to ActiGraph’s cloud-based Study Admin platform, giving ...
    Breaking Biology Technology:Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6ActiGraph Launches GT9X Link Activity Monitor 2
    ... ... ... ... , ...
    ... ... for different body types and shampoo bottles shaped to closely match the size of ... to redesign armor for troops in Afghanistan. , ... Madison, NJ, USA (PRWEB) February 24, 2010 -- Interactive exhibits make learning ...
    ... ... ... , ... , , , , ...
    Cached Biology Technology:Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 2Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 3Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 4Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 5Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 6Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 7Science by the Seat of Their Pants - Museum Goers, Industry and the Military Take Pressure Off with Body Mapping 2Science by the Seat of Their Pants - Museum Goers, Industry and the Military Take Pressure Off with Body Mapping 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 2Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 4Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 5
    (Date:11/5/2014)... professor of biology in the UTSA College of ... nation selected to receive a two-year $300,00 National ... Research (EAGER). The funding supports President Obama,s BRAIN ... create new technology that will demystify complex brain ... in neuroscience are broken into the interactions of ...
    (Date:11/4/2014)... CITY, Nov. 5, 2014 – University of Utah engineers ... to help jet fuel produce electricity without needing to ... used to power portable electronics, off-grid power and sensors. ... today in the American Chemical Society journal ACS ... through a chemical reaction between a fuel and an ...
    (Date:11/4/2014)... — Think about the way our bodies are assembled ... know that they are supposed to become a nerve ... find the correct place and alignment? Researchers at the ... , In a new study, UM researchers describe the ... surrounding neighbors, at the head-trunk region. Their discovery may ...
    Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2The inside story: How the brain and skull stay together 2
    ... Information Network Studies (CWINS) at Worcester Polytechnic Institute (WPI) ... National Institute of Standards and Technology (NIST) to conduct ... around and through the human body. Led by Kaveh ... of CWINS, the research will help speed the development ...
    ... from the Robertson Foundation to create a state-of-the-art Translational ... cell therapy research and treatment programs for children and ... suffered at birth. In making the announcement, Victor J. ... Chief Executive Officer for Duke University Health System, said ...
    ... the world will be at the Marriott in Walnut ... Institute 5th Annual Genomics of Energy and Environment Meeting, ... clean energy generation and the environment. Keynote speeches will ... Joint BioEnergy Institute, Steve Pennell of Ceres Inc. on ...
    Cached Biology News:WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 2WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 3Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 2Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 3DOE Joint Genome Institute 5th Annual Meeting on March 24-26, 2010 2
    ... The BD PhosFlow Perm/Wash Buffer I ... post-translationally modified signaling proteins to permeabilize cells ... and cell wash buffer. Because saponin-mediated cell ... important to keep the cells in the ...
    Mouse polyclonal antibody raised against a partial recombinant PREB. NCBI Entrez Gene ID = 10113...
    Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
    ... The user-friendly Eppendorf Thermomixer R ... preparations that require shaking, heating, and ... greatly expanded its application and temperature ... can each accommodate 24 micro test ...
    Biology Products: